Design of a Randomized Placebo-Controlled Trial to Evaluate the Anti-inflammatory and Senolytic Effects of Quercetin in Patients Undergoing Coronary Artery Bypass Graft Surgery

Study answer

What this study found

Background: Following an acute coronary syndrome, patients display an elevated inflammatory profile, promoted in part by cellular senescence. For patients requiring a coronary artery bypass (CABG) surgery, exposure to the surgical intervention and cardiopulmonary bypass further exacerbate their residual inflammation. Experimental evidence identified quercetin, a natural senolytic drug, as a cardioprotective agent against inflammatory injuries. The Q-CABG study aims to explore the efficacy of quercetin to reduce inflammation, myocardial injury and senescence in patients undergoing CABG…

A separate results summary is not available, so this answer uses the paper abstract.

Study & population

Phase II, single-center, prospective, randomized, double-blind, allocation-concealed, placebo-controlled trial at the Montreal Heart Institute; 100 adults (18+ years) with acute coronary syndrome diagnosed within the prior 30 days and scheduled for inpatient CABG.

Intervention

Quercetin 500 mg orally twice daily, starting 2-3 days before planned CABG and continuing after surgery until hospital discharge or up to seven postoperative days.

Key limitation

Quercetin is not an inflammation-specific agent; biomarker endpoints may not fully reflect anti-inflammatory effects.

View full study detailsView sourceOpen PDF

Original abstract